封面
市場調查報告書
商品編碼
1452786

全球寵物癌症治療市場規模、佔有率、成長分析,依治療(化療、放射治療)、依動物(狗、貓)、依應用(淋巴瘤、肥大細胞癌)-產業預測 2024-2031

Global Pet Cancer Therapeutics Market Size, Share, Growth Analysis, By Therapy(Chemotherapy, Radiation therapy), By Animal(Dogs, Cats), By Application(Lymphoma, Mast Cell Cancer) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球寵物癌症治療市場規模為2.7391億美元,預計將從2023年的3.024億美元成長到2031年的6.6731億美元,在預測期內(2024-2031年)複合年成長率為10.4%。

全球寵物癌症治療市場在更廣泛的寵物醫療保健領域內的關注和創新正在顯著激增。隨著寵物主人越來越重視動物夥伴的福祉,對寵物有效的癌症治療方案的需求也隨之增加。人們對寵物健康意識的增強以及為寵物提供最佳護理的願望推動了這一趨勢。市場參與者正在透過開發專門針對寵物的新療法來回應,為被診斷出患有癌症的動物帶來增強結果和改善生活品質的希望。此外,獸醫腫瘤學的進步有助於加深對寵物癌症的了解,促進標靶治療的發展。整體而言,寵物癌症治療市場呈現出一個充滿活力的格局,同情心和科學進步匯聚在一起,以滿足心愛的動物夥伴獨特的醫療保健需求。

目錄

執行摘要

  • 市場概況
  • 命運之輪

研究方法論

  • 資訊採購
  • 二手和主要資料來源
  • 市場規模估計
  • 市場假設與限制

母公司市場分析

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題

主要市場洞察

  • 技術分析
  • 定價分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • 啟動分析
  • 原料分析
  • 創新矩陣
  • 管道產品分析
  • 總體經濟指標
  • 頂級投資分析
  • 成功的關鍵因素
  • 競爭程度

市場動態與展望

  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題
  • 監管環境
  • 波特分析
  • 對未來顛覆的特別見解

依療法分類的全球寵物癌症治療市場

  • 市場概況
  • 化療
  • 放射治療
  • 免疫療法
  • 標靶治療
  • 其他療法

全球寵物癌症治療市場(依動物)

  • 市場概況
  • 小狗
  • 其他動物

全球寵物癌症治療市場(依應用)

  • 市場概況
  • 淋巴瘤
  • 肥大細胞癌
  • 黑色素瘤
  • 乳房
  • 和鱗狀細胞癌
  • 其他應用

全球寵物癌症治療市場規模(依地區)

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • MEA 的其餘部分

競爭格局

  • 前 5 名企業比較
  • 2021 年關鍵參與者的市場定位
  • 主要市場參與者所採取的策略
  • 最佳制勝策略
  • 近期市集活動
  • 主要公司市佔率(%),2021年

主要公司簡介

  • Aratana Therapeutics (US)
  • Elanco Animal Health (US)
  • Vetivax (US)
  • Anivive Lifesciences (US)
  • Regeneus (Australia)
  • Qbiotics (Australia)
  • Zoetis (US)
  • VetDC (US)
  • AB Science (France)
  • Merial (France)
  • VET Therapeutics (US)
  • Vet Cancer Group (US)
  • VetriScience (US)
  • Vetnostics (Australia)
  • Veterinary Cancer Group (US)
  • PetCure Oncology (US)
  • Veterinary Cancer Society (US)
  • PetCure Oncology (US)
  • Oasmia Pharmaceutical (Sweden)
簡介目錄
Product Code: SQMIG35I2256

Global Pet Cancer Therapeutics Market size was valued at USD 273.91 million in 2022 and is poised to grow from USD 302.40 million in 2023 to USD 667.31 million by 2031, growing at a CAGR of 10.4% during the forecast period (2024-2031).

The global market for pet cancer therapeutics is experiencing a significant surge in attention and innovation within the broader realm of pet healthcare. With pet owners placing greater emphasis on the well-being of their animal companions, the demand for effective cancer treatment options for pets has risen. This trend is fueled by an increasing awareness of pet health and the desire to provide optimal care for pets. Market players are responding by developing new therapeutics specifically tailored to pets, offering hope for enhanced outcomes and improved quality of life for animals diagnosed with cancer. Furthermore, advancements in veterinary oncology are contributing to a deeper understanding of cancer in pets, facilitating the development of targeted therapies. Overall, the pet cancer therapeutics market represents a dynamic landscape where compassion and scientific advancement converge to address the distinctive healthcare needs of beloved animal companions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pet Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pet Cancer Therapeutics Market Segmental Analysis

The global pet cancer therapeutics market is segmented into four segments therapy, animal, application and region. Based on therapy the market is segmented as, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and other therapies. Based on animal, the market is bifurcated as, dogs, cats, other animals. On the basis of application the market is segmented as, lymphoma, mast cell cancer, melanoma, mammary, and squamous cell cancer, other applications. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Pet Cancer Therapeutics Market

The burgeoning global pet cancer therapeutics market is significantly fueled by the rising phenomenon of pet humanization, wherein pet owners increasingly perceive their furry companions as indispensable family members. This shift in perspective drives a notable surge in investments towards advanced healthcare solutions, particularly cancer treatments, for pets. Consequently, there's a heightened demand for compassionate and efficacious cancer therapeutics specifically designed for pets, fostering innovation and expansion within the market.

Restraints in the Global Pet Cancer Therapeutics Market

A major obstacle in the worldwide pet cancer therapeutics sector is the exorbitant expense tied to cancer care for pets, covering diagnostics, surgeries, radiation therapy, and medication. These costs can impose significant financial strain on pet guardians, restricting access to advanced cancer treatments and forcing them to make tough decisions regarding their pets' care options. Consequently, despite the growing demand and awareness surrounding pet cancer therapeutics, affordability emerges as a pivotal concern, influencing market dynamics and the accessibility of these treatments.

Market Trends of the Global Pet Cancer Therapeutics Market

A notable trend in the global market for pet cancer therapeutics is the increasing focus on personalized treatment strategies, acknowledging the individuality of each pet's cancer diagnosis and therapeutic needs. This emphasis is fueling the need for customized therapeutic options, encompassing precision medicine and targeted therapies, as well as advancements in diagnostic techniques like genetic profiling and molecular testing. As a result, treatment regimens can be tailored to the unique features of a pet's cancer, enhancing treatment effectiveness and possibly minimizing adverse effects. This transition towards personalized care underscores a rising dedication to improving the standard of care and outcomes for pets grappling with cancer.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Pet Cancer Therapeutics Market by Therapy

  • Market Overview
  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Targeted Therapy
  • and Other Therapies

Global Pet Cancer Therapeutics Market by Animal

  • Market Overview
  • Dogs
  • Cats
  • Other Animals

Global Pet Cancer Therapeutics Market by Application

  • Market Overview
  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary
  • and Squamous Cell Cancer
  • Other Applications

Global Pet Cancer Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Aratana Therapeutics (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Elanco Animal Health (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vetivax (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Anivive Lifesciences (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneus (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Qbiotics (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zoetis (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • VetDC (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AB Science (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merial (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • VET Therapeutics (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vet Cancer Group (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • VetriScience (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vetnostics (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Veterinary Cancer Group (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PetCure Oncology (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Veterinary Cancer Society (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PetCure Oncology (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oasmia Pharmaceutical (Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments